Breast Cancer Research and Treatment

, Volume 88, Issue 1, pp 63–73

Factors associated with circulating levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in 740 women at risk for breast cancer

  • Harriet Johansson
  • Laura Baglietto
  • Aliana Guerrieri-gonzaga
  • Bernardo Bonanni
  • Frederique Mariette
  • Debora Macis
  • Davide Serrano
  • Maria Teresa sandri
  • Andrea Decensi
Article

Abstract

Prospective studies have shown an association between elevated plasma levels of insulin-like growth factor-I (IGF-I) and/or decreased levels of its major circulating carrier protein insulin-like growth factor binding protein-3 (IGFBP-3) and increased risk of major cancers. Identifying the factors which affect these biomarkers is of particular interest as subjects at increased risk could benefit from lifestyle changes, and/or chemoprevention intervention. We evaluated the association between constitutional, hormonal and clinical factors and IGF-I and IGFBP-3 in 740 women, including 376 unaffected women and 364 women with intraepithelial neoplasia (IEN) or early invasive breast cancer enrolled in breast cancer chemoprevention trials, conducted at a single institution. Age, body mass index (BMI), height, waist to hip girth ratio (WHR), parity, menopausal status, age at menarche, number of affected first degree relatives, number of biopsies and breast cancer status were considered in the analysis. Women with early breast cancer had 21% higher IGF-I levels ( p=0.033) and 19% higher IGF-I/IGFBP-3 molar ratio ( p=0.047) than unaffected women. In unaffected women, age was negatively associated with IGF-I ( p=0.002) and IGF-I/IGFBP-3 ( p=0.001), while age at menarche was negatively associated with IGFBP-3 levels ( p=0.043). In women with IEN or early breast cancer, IGF-I levels were negatively associated with age ( p < 0.001), and positively associated with prior biopsies for benign disease ( p=0.013), while age, parity and menopausal status were significant predictors of IGF-I/IGFBP-3 molar ratio. We conclude that circulating IGF-I levels are higher in women with prior breast cancer compared to unaffected women, and that IGF-I and/or IGFBP-3 levels are influenced by age and by reproductive and hormonal factors. These findings support their putative role as breast cancer risk biomarker.

biomarkers breast cancer chemoprevention IGF-I IGFBP-3 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Jones JI, Clemmons DR: Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16: 3–34, 1995Google Scholar
  2. 2.
    Schedlich LJ, Graham LD: Role of insulin-like growth factor binding protein-3 in breast cancer cell growth. Microsc Res Tech 59: 12–22, 2002Google Scholar
  3. 3.
    Yu H, Rohan T: Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 92: 1472–1489, 2000Google Scholar
  4. 4.
    Ng ST, Zhou J, Adesanya OO, Wang J, LeRoith D, Bondy CA: Growth hormone treatment induces mammary gland hyperplasia in aging primates. Nat Med 3: 1141–1144, 1997Google Scholar
  5. 5.
    Hadsell DL, Murphy KL, Bonnette SG, Reece N, Laucirica R, Rosen JM: Cooperative interaction between mutant p53 and des(1–3)IGF-I accelerates mammary tumorigenesis. Oncogene 19: 889–898, 2000Google Scholar
  6. 6.
    Dunn SE, Kari FW, French J, Leininger JR, Travlos G, Wilson R, Barrett JC: Dietary restriction reduces insulinlike growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53–deficient mice. Cancer Res 57: 4667–4672, 1997Google Scholar
  7. 7.
    Giovannucci E, Pollak MN, Platz EA, Willett WC, Stampfer MJ, Majeed N, Colditz GA, Speizer FE, Hankinson SE: A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Prev 9: 345–349, 2000Google Scholar
  8. 8.
    Lukanova A, Lundin E, Toniolo P, Micheli A, Akhmedkhanov A, Rinaldi S, Muti P, Lenner P, Biessy C, Krogh V, Zeleniuch-Jacquotte A, Berrino F, Hallmans G, Riboli E, Kaaks R: Circulating levels of insulin-like growth factor-I and risk of ovarian cancer. Int J Cancer 101: 549–554, 2002Google Scholar
  9. 9.
    Lukanova A, Toniolo P, Akhmedkhanov A, Biessy C, Haley NJ, Shore RE, Riboli E, Rinaldi S, Kaaks R: A prospective study of insulin-like growth factor-I, IGFbinding proteins-1,-2 and-3 and lung cancer risk in women. Int J Cancer 92: 888–892, 2001Google Scholar
  10. 10.
    Toniolo P, Bruning PF, Akhmedkhanov A, Bonfrer JM, Koenig KL, Lukanova A, Shore RE, Zeleniuch-Jacquotte A: Serum insulin-like growth factor-I and breast cancer. Int J Cancer 88: 828–832, 2000Google Scholar
  11. 11.
    Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M: Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351: 1393–1396, 1998Google Scholar
  12. 12.
    Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M: Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279: 563–566, 1998Google Scholar
  13. 13.
    London SJ, Yuan JM, Travlos GS, Gao YT, Wilson RE, Ross RK, Yu MC: Insulin-like growth factor I, IGFbinding protein 3, and lung cancer risk in a prospective study of men in China. J Natl Cancer Inst 94: 749–754, 2002Google Scholar
  14. 14.
    Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, Stampfer MJ: Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 91: 620–625, 1999Google Scholar
  15. 15.
    Bohlke K, Cramer DW, Trichopoulos D, Mantzoros CS: Insulin-like growth factor-I in relation to premenopausal ductal carcinoma in situ of the breast. Epidemiology 9: 570–573, 1998Google Scholar
  16. 16.
    Bruning PF, Van Doorn J, Bonfrer JM, Van Noord PA, Korse CM, Linders TC, Hart AA: Insulin-like growthfactor-binding protein 3 is decreased in early-stage operable pre-menopausal breast cancer. Int J Cancer 62: 266–270, 1995Google Scholar
  17. 17.
    Peyrat JP, Bonneterre J, Hecquet B, Vennin P, Louchez MM, Fournier C, Lefebvre J, Demaille A: Plasma insulinlike growth factor-1 (IGF-1) concentrations in human breast cancer. Eur J Cancer 29A: 492–497, 1993Google Scholar
  18. 18.
    Yu H, Jin F, Shu XO, Li BD, Dai Q, Cheng JR, Berkel HJ, Zheng W: Insulin-like growth factors and breast cancer risk in Chinese women. Cancer Epidemiol Biomarkers Prev 11: 705–712, 2002Google Scholar
  19. 19.
    Byrne C, Colditz GA, Willett WC, Speizer FE, Pollak M, Hankinson SE: Plasma insulin-like growth factor (IGF) I, IGF-binding protein 3, and mammographic density. Cancer Res 60: 3744–3748, 2000Google Scholar
  20. 20.
    Decensi A, Bonanni B, Guerrieri-Gonzaga A, Gandini S, Robertson C, Johansson H, Travaglini R, Sandri MT, Tessadrelli A, Farante G, Salinaro F, Bettega D, Barreca A, Boyle P, Costa A, Veronesi U: Biologic activity of tamoxifen at low doses in healthy women. J Natl Cancer Inst 90: 1461–1467, 1998Google Scholar
  21. 21.
    Decensi A, Omodei U, Robertson C, Bonanni B, Guerrieri-Gonzaga A, Ramazzotto F, Johansson H, Mora S, Sandri MT, Cazzaniga M, Franchi, M Pecorelli S: Effect of transdermal estradiol and oral conjugated estrogen on Creactive protein in retinoid-placebo trial in healthy women. Circulation 106: 1224–1228, 2002Google Scholar
  22. 22.
    Torrisi R, Baglietto L, Johansson H, Veronesi G, Bonanni B, Guerrieri-Gonzaga A, Ballardini B, Decensi A: Effect of raloxifene on IGF-I and IGFBP-3 in postmenopausal women with breast cancer. Br J Cancer 85: 1838–1841, 2001Google Scholar
  23. 23.
    Decensi A, Robertson C, Viale G, Pigatto F, Johansson H, Kisanga ER, Veronesi P, Torrisi R, Cazzaniga M, Mora S, Sandri MT, Pelosi G, Luini A, Goldhirsch A, Lien EA, Veronesi U: A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J Natl Cancer Inst 95: 779–790, 2003Google Scholar
  24. 24.
    Bonanni B, Johansson H, Gandini S, Guerrieri-Gonzaga A, Torrisi R, Sandri MT, Cazzaniga M, Mora S, Robertson C, Lien EA, Decensi A: Effect of low dose tamoxifen on the insulin-like growth factor system in healthy women. Breast Cancer Res Treat 69: 21–27, 2001Google Scholar
  25. 25.
    Kaaks R, Lundin E, Rinaldi S, Manjer J, Biessy C, Soderberg S, Lenner P, Janzon L, Riboli E, Berglund G, Hallmans G: Prospective study of IGF-I, IGF-binding proteins, and breast cancer risk, in northern and southern Sweden. Cancer Causes Control 13: 307–316, 2002Google Scholar
  26. 26.
    Clarke RB, Howell A, Anderson E: Type I insulin-like growth factor receptor gene expression in normal human breast tissue treated with oestrogen and progesterone. Br J Cancer 75: 251–257, 1997Google Scholar
  27. 27.
    Lai A, Sarcevic B, Prall OW, Sutherland RL: Insulin/insulin-like growth factor-I and estrogen cooperate to stimulate cyclin E-Cdk2 activation and cell Cycle progression in MCF-7 breast cancer cells through differential regulation of cyclin E and p21(WAF1/Cip1). J Biol Chem 276: 25823–25833, 2001Google Scholar
  28. 28.
    Yu H, Shu XO, Li BDL, Dai Q, Gao YT, Jin F, Zheng W: Joint effect of insulin-like growth factors and sex steroids on breast cancer risk. Cancer Epidemiol Biomarkers Prev 12: 1067–1073, 2003Google Scholar
  29. 29.
    Helle SI, Geisler S, Aas T, Paulsen T, Holly JM, Lonning PE: Plasma insulin-like growth factor binding protein-3 proteolysis is increased in primary breast cancer. Br J Cancer 85: 74–77, 2001Google Scholar
  30. 30.
    Goodman-Gruen D, Barrett-Connor E: Epidemiology of insulin-like growth factor-I in elderly men and women. The Rancho Bernardo study. AmJ Epidemiol 145: 970–976, 1997Google Scholar
  31. 31.
    Juul A, Bang P, Hertel NT, Main K, Dalgaard P, Jorgensen K, Muller J, Hall K, Skakkebaek NE: Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin EndocrinolMetab 78: 744–752, 1994Google Scholar
  32. 32.
    Landin-Wilhelmsen K, Wilhelmsen L, Lappas G, Rosen T, Lindstedt G, Lundberg PA, Bengtsson BA: Serum insulinlike growth factor I in a random population sample of men and women: relation to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid hormone and osteocalcin. Clin Endocrinol 41: 351–357, 1994Google Scholar
  33. 33.
    Juul A, Main K, Blum WF, Lindholm J, Ranke MB, Skakkebaek NE: The ratio between serum levels of insulin-like growth factor (IGF)-I and the IGFbinding proteins (IGFBP-1, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients. Clin Endocrinol 41: 85–93, 1994Google Scholar
  34. 34.
    Benbassat CA, Maki KC, Unterman TG: Circulating levels of insulin-like growth factor (IGF) binding protein-1 and-3 in aging men: relationships to insulin, glucose, IGF, and dehydroepiandrosterone sulfate levels and anthropometric measures. J Clin Endocrinol Metab 82: 1484–1491, 1997Google Scholar
  35. 35.
    Harris TB, Kiel D, Roubenoff R, Langlois J, Hannan M, Havlik R, Wilson P: Association of insulin-like growth factor-I with body composition, weight history, and past health behaviors in the very old: the Framingham Heart Study. J Am Geriatr Soc 45: 133–139, 1997Google Scholar
  36. 36.
    Maccario M, Ramunni J, Oleandri SE, Procopio M, Grottoli S, Rossetto R, Savio P, Aimaretti G, Camanni F, Ghigo E: Relationships between IGF-I and age, gender, body mass, fat distribution, metabolic and hormonal variables in obese patients. Int J Obes Relat Metab Disord 23: 612–618, 1999Google Scholar
  37. 37.
    Kaaks R, Lukanova A: Energy balance and cancer: the role of insulin and insulin-like growth factor-I. Proc Nutr Soc 60: 91–106, 2001Google Scholar
  38. 38.
    Thissen JP, Ketelslegers JM, Underwood LE: Nutritional regulation of the insulin-like growth factors. Endocr Rev 15: 80–101, 1994Google Scholar
  39. 39.
    Lukanova A, Soderberg S, Stattin P, Palmqvist R, Lundin E, Biessy C, Rinaldi S, Riboli E, Hallmans G, Kaaks R: Nonlinear relationship of insulin-like growth factor (IGF)-I and IGF-I/IGF-binding protein-3 ratio with indices of adiposity and plasma insulin concentrations (Sweden). Cancer Causes Control 13: 509–516, 2002Google Scholar
  40. 40.
    Holmes MD, Pollak MN, Hankinson SE: Lifestyle correlates of plasma insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations. Cancer Epidemiol Biomarkers Prev 11: 862–867, 2002Google Scholar
  41. 41.
    Jernstrom H, Deal C, Wilkin F, Chu W, Tao Y, Majeed N, Hudson T, Narod SA, Pollak M: Genetic and nongenetic factors associated with variation of plasma levels of insulinlike growth factor-I and insulin-like growth factor-binding protein-3 in healthy premenopausal women. Cancer Epidemiol Biomarkers Prev 10: 377–384, 2001Google Scholar
  42. 42.
    Thierry van Dessel HJ, Chandrasekher Y, Yap OW, Lee PD, Hintz RL, Faessen GH, Braat DD, Fauser BC, Giudice LC: Serum and follicular fluid levels of insulinlike growth factor I (IGF-I), IGF-II, and IGF-binding protein-1 and-3 during the normal menstrual cycle. J Clin Endocrinol Metab 81: 1224–1231, 1996Google Scholar
  43. 43.
    Wang HS, Lee JD, Soong YK: Serum levels of insulin-like growth factor I and insulin-like growth factor-binding protein-1 and-3 in women with regular menstrual cycles. Fertil Steril 63: 1204–1209, 1995Google Scholar
  44. 44.
    Dabrosin C: Increase of free insulin-like growth factor-1 in normal human breast in vivo late in the menstrual cycle. Breast Cancer Res Treat 80: 193–198, 2003Google Scholar
  45. 45.
    Juul A: The effects of oestrogens on linear bone growth. Hum Reprod Update 7: 303–313, 2001Google Scholar
  46. 46.
    Surmacz E, Guvakova MA, NolanMK, Nicosia RF, Sciacca L: Type I insulin-like growth factor receptor function in breast cancer. Breast Cancer Res Treat 47: 255–267, 1998Google Scholar
  47. 47.
    Hamilton AS, Mack TM: Puberty and genetic susceptibility to breast cancer in a case-control study in twins. N Engl J Med 348: 2313–2322, 2003Google Scholar
  48. 48.
    Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, Mulvihill JJ: Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81: 1879–1886, 1989Google Scholar

Copyright information

© Kluwer Academic Publishers 2004

Authors and Affiliations

  • Harriet Johansson
    • 1
  • Laura Baglietto
    • 2
  • Aliana Guerrieri-gonzaga
    • 1
  • Bernardo Bonanni
    • 1
  • Frederique Mariette
    • 1
  • Debora Macis
    • 1
  • Davide Serrano
    • 1
  • Maria Teresa sandri
    • 3
  • Andrea Decensi
    • 1
    • 4
  1. 1.Divisions of ChemopreventionEuropean Institute of OncologyItaly
  2. 2.Cancer Epidemiology CentreThe Cancer Council VictoriaAustralia
  3. 3.Laboratory MedicineEuropean Institute of OncologyItaly
  4. 4.Division of Medical and Preventive OncologyGalliera HospitalItaly

Personalised recommendations